...
首页> 外文期刊>British journal of neurosurgery >Effectiveness of combining continuous cerebrospinal drainage and intermittent intrathecal urokinase injection therapy in preventing symptomatic vasospasm following aneurysmal subarachnoid haemorrhage.
【24h】

Effectiveness of combining continuous cerebrospinal drainage and intermittent intrathecal urokinase injection therapy in preventing symptomatic vasospasm following aneurysmal subarachnoid haemorrhage.

机译:连续性脑脊髓引流和间歇性鞘内尿激酶注射治疗相结合,可有效预防动脉瘤性蛛网膜下腔出血后的症状性血管痉挛。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The effect of cisternal drainage and intrathecal urokinase (UK) injections in preventing symptomatic vasospasm after aneurysmal subarachnoid haemorrhage was retrospectively studied in 69 patients with uniform backgrounds with regard to subarachnoid haemorrhage (SAH; WFNS grade I to IV, Fisher's group 3, undergoing surgery or coil embolization within 72 h of the onset). With regard to the selection of patients, 34 patients belonging to the control group (no UK injection group) underwent the treatment during the 3-year period from 2001 to 2003, while 35 patients belonging to the UK group underwent the treatment during the 3-year period from 2004 to 2006. The incidence of symptomatic vasospasm was 5/35 with the UK group, but 12/34 with a control group. The UK injection significantly reduced the incidence of symptomatic vasospasm (p = 0.042, Pearson chi-square test), resulting in an improvement shown by the Glasgow Outcome Scale (GOS; p = 0.030, Mann-Whitney U test; Table V). The distribution on the angiographic grading scales for cerebral vasospasm significantly shifted in a positive direction for the UK group (mild 0, moderate 5, severe 0) in comparison with the control group (mild 0, moderate 4, severe 8; p = 0.014, Mann-Whitney U test). This study suggests that combining continuous cerebrospinal drainage and intermittent intrathecal UK injection therapy is a relatively simple and effective method for symptomatic vasospasm prophylaxis in patients with aneurysmal SAH.
机译:回顾性研究了69例背景相同的蛛网膜下腔出血(SAH; WFNS I至IV级,Fisher的第3组,接受手术或手术治疗)的患者,回顾性研究了脑池引流和鞘内尿激酶(UK)注射预防动脉瘤性蛛网膜下腔出血后症状性血管痉挛的效果。在发作后72小时内进行线圈栓塞)。关于患者的选择,在2001年至2003年的3年中,有34名属于对照组(无UK注射组)的患者接受了治疗,而有3名属于UK组的患者在3年期间接受了治疗。从2004年到2006年的一年期间。有症状的血管痉挛的发生率在英国组为5/35,在对照组中为12/34。英国注射显着降低了症状性血管痉挛的发生率(P = 0.042,皮尔逊卡方检验),结果通过格拉斯哥结果量表(GOS; p = 0.030,Mann-Whitney U检验;表V)显示有所改善。与对照组(轻度0,中度4,重度8; p = 0.014)相比,UK组(轻度0,中度5,重度0)在脑血管痉挛的血管造影分级量表上的分布显着向正方向移动。 Mann-Whitney U检验)。这项研究表明,连续性脑脊髓引流和间断鞘内UK注射疗法相结合是预防动脉瘤SAH患者症状性血管痉挛的一种相对简单有效的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号